172 related articles for article (PubMed ID: 26033834)
21. Raman spectroscopy for the preoperative diagnosis of thyroid cancer and its subtypes: An in vitro proof-of-concept study.
O'Dea D; Bongiovanni M; Sykiotis GP; Ziros PG; Meade AD; Lyng FM; Malkin A
Cytopathology; 2019 Jan; 30(1):51-60. PubMed ID: 30276947
[TBL] [Abstract][Full Text] [Related]
22. Performance of a dual-component molecular assay in cytologically indeterminate thyroid nodules.
Sponziello M; Brunelli C; Verrienti A; Grani G; Pecce V; Abballe L; Ramundo V; Damante G; Russo D; Lombardi CP; Durante C; Rossi ED; Straccia P; Fadda G; Filetti S
Endocrine; 2020 May; 68(2):458-465. PubMed ID: 32232767
[TBL] [Abstract][Full Text] [Related]
23. Molecular-Directed Treatment of Differentiated Thyroid Cancer: Advances in Diagnosis and Treatment.
Yip L; Sosa JA
JAMA Surg; 2016 Jul; 151(7):663-70. PubMed ID: 27223483
[TBL] [Abstract][Full Text] [Related]
24. Molecular testing for thyroid nodules: Review and current state.
Roth MY; Witt RL; Steward DL
Cancer; 2018 Mar; 124(5):888-898. PubMed ID: 29278433
[TBL] [Abstract][Full Text] [Related]
25. Impact of the Afirma Gene Expression Classifier Result on the Surgical Management of Thyroid Nodules with Category III/IV Cytology and Its Correlation with Surgical Outcome.
Chaudhary S; Hou Y; Shen R; Hooda S; Li Z
Acta Cytol; 2016; 60(3):205-10. PubMed ID: 27344463
[TBL] [Abstract][Full Text] [Related]
26. Cytopathology of Follicular Cell Nodules.
Rossi ED; Bizzarro T; Martini M; Larocca LM; Schmitt F; Vielh P
Adv Anat Pathol; 2017 Jan; 24(1):45-55. PubMed ID: 27941541
[TBL] [Abstract][Full Text] [Related]
27. Differentiating malignant from benign thyroid nodules with indeterminate cytology by
Campennì A; Siracusa M; Ruggeri RM; Laudicella R; Pignata SA; Baldari S; Giovanella L
Sci Rep; 2017 Jul; 7(1):6147. PubMed ID: 28733644
[TBL] [Abstract][Full Text] [Related]
28. The Afirma Xpression Atlas for thyroid nodules and thyroid cancer metastases: Insights to inform clinical decision-making from a fine-needle aspiration sample.
Krane JF; Cibas ES; Endo M; Marqusee E; Hu MI; Nasr CE; Waguespack SG; Wirth LJ; Kloos RT
Cancer Cytopathol; 2020 Jul; 128(7):452-459. PubMed ID: 32543766
[TBL] [Abstract][Full Text] [Related]
29. Real-world Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules.
San Martin VT; Lawrence L; Bena J; Madhun NZ; Berber E; Elsheikh TM; Nasr CE
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31665322
[TBL] [Abstract][Full Text] [Related]
30. Role of Ancillary Techniques in Thyroid Cytology Specimens.
Nishino M; Krane JF
Acta Cytol; 2020; 64(1-2):40-51. PubMed ID: 30947167
[TBL] [Abstract][Full Text] [Related]
31. Pathologic significance of a novel oncoprotein in thyroid cancer progression.
Firek AA; Perez MC; Gonda A; Lei L; Munir I; Simental AA; Carr FE; Becerra BJ; De Leon M; Khan S
Head Neck; 2017 Dec; 39(12):2459-2469. PubMed ID: 29024261
[TBL] [Abstract][Full Text] [Related]
32. One-stop thyroid nodule clinic with same-day fine-needle aspiration cytology improves efficiency of care.
Patel R; R Skandarajah A; Gorelik A; Shears MJ; Tasevski R; Miller JA
ANZ J Surg; 2018 Apr; 88(4):354-358. PubMed ID: 27788561
[TBL] [Abstract][Full Text] [Related]
33. Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and
Hernandez-Prera JC; Valderrabano P; Creed JH; de la Iglesia JV; Slebos RJC; Centeno BA; Tarasova V; Hallanger-Johnson J; Veloski C; Otto KJ; Wenig BM; Yoder SJ; Lam CA; Park DS; Anderson AR; Raghunand N; Berglund A; Caudell J; Gerke TA; Chung CH
Thyroid; 2021 Jan; 31(1):36-49. PubMed ID: 32689909
[No Abstract] [Full Text] [Related]
34. Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier.
Randolph GW; Sosa JA; Hao Y; Angell TE; Shonka DC; LiVolsi VA; Ladenson PW; Blevins TC; Duh QY; Ghossein R; Harrell M; Patel KN; Shanik MH; Traweek ST; Walsh PS; Yeh MW; Abdelhamid Ahmed AH; Ho AS; Wong RJ; Klopper JP; Huang J; Kennedy GC; Kloos RT; Sadow PM
Thyroid; 2022 Sep; 32(9):1069-1076. PubMed ID: 35793115
[No Abstract] [Full Text] [Related]
35. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract][Full Text] [Related]
36. Association of Bethesda category and molecular mutation in patients undergoing thyroidectomy.
Mascarella MA; Peeva M; Forest VI; Pusztaszeri MP; Avior G; Tamilia M; Mlynarek AM; Hier MP; Payne RJ
Clin Otolaryngol; 2022 Jan; 47(1):75-80. PubMed ID: 34510770
[TBL] [Abstract][Full Text] [Related]
37. Quantifying the differences in surgical management of patients with definitive and indeterminate thyroid nodule cytology.
Stewart R; Leang YJ; Bhatt CR; Grodski S; Serpell J; Lee JC
Eur J Surg Oncol; 2020 Feb; 46(2):252-257. PubMed ID: 31648951
[TBL] [Abstract][Full Text] [Related]
38. Update on Molecular Testing for Cytologically Indeterminate Thyroid Nodules.
Bose S; Sacks W; Walts AE
Adv Anat Pathol; 2019 Mar; 26(2):114-123. PubMed ID: 30664001
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of PACE4 isoforms as biomarkers in thyroid cancer.
Fradet L; Temmar R; Couture F; Belzile M; Fortier PH; Day R
J Otolaryngol Head Neck Surg; 2018 Oct; 47(1):63. PubMed ID: 30340539
[TBL] [Abstract][Full Text] [Related]
40. Molecular Characterization of Thyroid Follicular Lesions in the Era of "Next-Generation" Techniques.
Rossi ED; Locantore P; Bruno C; Dell'Aquila M; Tralongo P; Curatolo M; Revelli L; Raffaelli M; Larocca LM; Pantanowitz L; Pontecorvi A
Front Endocrinol (Lausanne); 2022; 13():834456. PubMed ID: 35634500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
